Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

SLC1A3 contributes to L-asparaginase resistance in solid tumors.

Sun J, Nagel R, Zaal EA, Ugalde AP, Han R, Proost N, Song JY, Pataskar A, Burylo A, Fu H, Poelarends GJ, van de Ven M, van Tellingen O, Berkers CR, Agami R.

EMBO J. 2019 Sep 16:e102147. doi: 10.15252/embj.2019102147. [Epub ahead of print]

2.

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H.

Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22.

PMID:
31011202
3.

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.

Nagel R, Avelar AT, Aben N, Proost N, van de Ven M, van der Vliet J, Cozijnsen M, de Vries H, Wessels LFA, Berns A.

Mol Cancer Ther. 2019 Apr;18(4):762-770. doi: 10.1158/1535-7163.MCT-18-0972. Epub 2019 Mar 14.

4.

Long-term expanding human airway organoids for disease modeling.

Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H, Dekkers JF, Kumawat K, Ramos E, van Oosterhout MF, Offerhaus GJ, Wiener DJ, Olimpio EP, Dijkstra KK, Smit EF, van der Linden M, Jaksani S, van de Ven M, Jonkers J, Rios AC, Voest EE, van Moorsel CH, van der Ent CK, Cuppen E, van Oudenaarden A, Coenjaerts FE, Meyaard L, Bont LJ, Peters PJ, Tans SJ, van Zon JS, Boj SF, Vries RG, Beekman JM, Clevers H.

EMBO J. 2019 Feb 15;38(4). pii: e100300. doi: 10.15252/embj.2018100300. Epub 2019 Jan 14.

5.

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.

Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.

6.

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, Morris B, Cesaroni M, Proost N, Beijersbergen RL, van Lohuizen M, Gargiulo G.

J Exp Med. 2018 Dec 3;215(12):3115-3135. doi: 10.1084/jem.20180801. Epub 2018 Nov 28.

7.

SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin.

Ferone G, Song JY, Sutherland KD, Bhaskaran R, Monkhorst K, Lambooij JP, Proost N, Gargiulo G, Berns A.

Cancer Cell. 2016 Oct 10;30(4):519-532. doi: 10.1016/j.ccell.2016.09.001.

8.

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.

Semenova EA, Kwon MC, Monkhorst K, Song JY, Bhaskaran R, Krijgsman O, Kuilman T, Peters D, Buikhuisen WA, Smit EF, Pritchard C, Cozijnsen M, van der Vliet J, Zevenhoven J, Lambooij JP, Proost N, van Montfort E, Velds A, Huijbers IJ, Berns A.

Cell Rep. 2016 Jul 19;16(3):631-43. doi: 10.1016/j.celrep.2016.06.020. Epub 2016 Jun 30.

9.

Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.

Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E, Orkin S, Berns A, van Lohuizen M.

Cancer Cell. 2016 Jan 11;29(1):17-31. doi: 10.1016/j.ccell.2015.12.006. Erratum in: Cancer Cell. 2016 Feb 8;29(2):241.

10.

Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis.

Kwon MC, Proost N, Song JY, Sutherland KD, Zevenhoven J, Berns A.

Genes Dev. 2015 Aug 1;29(15):1587-92. doi: 10.1101/gad.262998.115. Epub 2015 Jul 27.

11.

Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis.

Heideman MR, Lancini C, Proost N, Yanover E, Jacobs H, Dannenberg JH.

Haematologica. 2014 Aug;99(8):1292-303. doi: 10.3324/haematol.2013.092643. Epub 2014 Apr 24.

12.

Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.

Sutherland KD, Song JY, Kwon MC, Proost N, Zevenhoven J, Berns A.

Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4952-7. doi: 10.1073/pnas.1319963111. Epub 2014 Feb 28.

13.

Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells.

Huijbers IJ, Bin Ali R, Pritchard C, Cozijnsen M, Kwon MC, Proost N, Song JY, de Vries H, Badhai J, Sutherland K, Krimpenfort P, Michalak EM, Jonkers J, Berns A.

EMBO Mol Med. 2014 Feb;6(2):212-25. doi: 10.1002/emmm.201303297. Epub 2014 Jan 8.

14.

Frat2 mediates the oncogenic activation of Rac by MLL fusions.

Walf-Vorderwülbecke V, de Boer J, Horton SJ, van Amerongen R, Proost N, Berns A, Williams O.

Blood. 2012 Dec 6;120(24):4819-28. doi: 10.1182/blood-2012-05-432534. Epub 2012 Oct 16.

PMID:
23074275
15.

Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours.

Krimpenfort P, Song JY, Proost N, Zevenhoven J, Jonkers J, Berns A.

Nature. 2012 Feb 22;482(7386):538-41. doi: 10.1038/nature10790.

PMID:
22358843
16.

Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A.

Cancer Cell. 2011 Jun 14;19(6):754-64. doi: 10.1016/j.ccr.2011.04.019.

17.

A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.

Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, Berns A.

Cancer Cell. 2011 Feb 15;19(2):244-56. doi: 10.1016/j.ccr.2010.12.021.

18.

Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways.

van Amerongen R, Nawijn MC, Lambooij JP, Proost N, Jonkers J, Berns A.

Oncogene. 2010 Jan 7;29(1):93-104. doi: 10.1038/onc.2009.310. Epub 2009 Oct 5.

PMID:
19802005
19.

Immune response in lung cancer mouse model mimics human anti-Hu reactivity.

Kazarian M, Calbo J, Proost N, Carpenter CL, Berns A, Laird-Offringa IA.

J Neuroimmunol. 2009 Dec 10;217(1-2):38-45. doi: 10.1016/j.jneuroim.2009.08.014. Epub 2009 Sep 17.

20.

[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.

Direcks WG, Berndsen SC, Proost N, Peters GJ, Balzarini J, Spreeuwenberg MD, Lammertsma AA, Molthoff CF.

Br J Cancer. 2008 Aug 5;99(3):481-7. doi: 10.1038/sj.bjc.6604523.

Supplemental Content

Loading ...
Support Center